Therapeutic Asset Ratings
243 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Zofran
Lymphoma
Fox Chase Cancer Center
P3
BB
(66)
Bendamustine
Lymphoma
Fox Chase Cancer Center
P3
BB
(65)
Rapamycin
Lymphoma
Center for International Blood and Marrow Transplant Research
P2
BB
(65)
Brentuximab Vedotin
Lymphoma
Chinese PLA General Hospital
P4
BB
(64)
Epirubicin
Lymphoma
Merck Sharp & Dohme LLC
P4
BB
(64)
Romidepsin
Lymphoma
National Cancer Institute (NCI)
P4
BB
(64)
Thiotepa
Lymphoma
Memorial Sloan Kettering Cancer Center
P4
BB
(64)
cc-5013
Lymphoma
Memorial Sloan Kettering Cancer Center
P3
BB
(64)
Ibrutinib
Lymphoma
Inhye Ahn
P3
BB
(64)
PEGFILGRASTIM
Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
P3
BB
(64)
TACROLIMUS
Lymphoma
National Cancer Institute (NCI)
P4
B
(63)
Anti-Thymoglobulin, Rabbit
Lymphoma
Peking University First Hospital
P4
B
(62)
Gm-Csf
Lymphoma
Medical College of Wisconsin
P4
B
(62)
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Lymphoma
Peking University
P4
B
(62)
Carboplatin
Lymphoma
Rehab Werida
P3
B
(62)
Venetoclax
Lymphoma
M.D. Anderson Cancer Center
P2
B
(62)
Eloxatin
Lymphoma
Brown University
P3
B
(61)
Mesna
Lymphoma
Center for International Blood and Marrow Transplant Research
P3
B
(61)
Obinutuzumab
Lymphoma
Brown University
P3
B
(61)
Chimeric Antigen Receptor Modified T Cells Infusion
Lymphoma
Chinese PLA General Hospital
P2
B
(61)
Rhgm-Csf
Lymphoma
Ou Bai, MD/PHD
P4
B
(60)
Bortezomib
Lymphoma
M.D. Anderson Cancer Center
P3
B
(60)
CARVEDILOL
Lymphoma
Mayo Clinic
P3
B
(60)
Glofitamab
Lymphoma
Brown University
P3
B
(60)
Idarubicine
Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
P3
B
(60)
Showing 26 to 50 of 243 assets
Previous
Page 2 of 10
Next
